A spectrum of non-spore-forming fermentative and non-fermentative Gram-negative bacteria: multi-drug resistance, extended-spectrum beta-lactamase, and carbapenemase production
- PMID: 39816652
- PMCID: PMC11732051
- DOI: 10.3389/frabi.2023.1155005
A spectrum of non-spore-forming fermentative and non-fermentative Gram-negative bacteria: multi-drug resistance, extended-spectrum beta-lactamase, and carbapenemase production
Abstract
Background: In developing countries, the co-existence of a high burden of infectious diseases caused by Gram-negative bacteria and the rapid increase and spread of multidrug-resistant bacteria have become a serious health threat.
Objective: Profiling of Gram-negative bacteria and determining the magnitude of their antimicrobial resistance among patients.
Results: A total of 175 non-spore-forming Gram-negative bacteria were isolated from 873 different clinical samples. Of a total of 175 bacteria, 154 (88%) were fermentative Gram-negative bacteria, while 21 (12%) were non-fermentative Gram-negative bacteria. E. coli with a frequency of 58.3% and K. pneumoniae with a frequency of 18.3% were the predominant fermentative Gram-negative bacteria, while P. aeruginosa 9 (5.1%) and A. baumannii 6 (3.4%) were the predominant non-fermentative Gram-negative bacteria. The highest percentage level of antibiotic resistance was seen against ampicillin (86%), and the lowest against meropenem (9.8). About 49 (28%) Gram-negative bacilli were positive for ESBLase. The overall prevalence rate of MDR bacteria was 80.5%, of which 100% of A. baumannii, 90.6% of K. pneumonia. Sixteen isolates were resistant to meropenem, out of which 11 tested for carbapenemase production. Five of the nine were metallo-lactamase producers, with the remaining four being serine carbapenemase producers.
Conclusion: The prevalence of Gram-negative bacterial infection was found to be 20%, with a significant proportion (80.0%) due to fermentative Gram-negative bacteria and the remaining 20% due to non-fermentative Gram-negative bacteria. The study has also demonstrated a high prevalence rate of MDR, ESBLase, and carbapenemase-producing Gram-negative bacteria. Antimicrobial resistance of Gram-negative bacteria should be monitored on a regular basis, and an effective infection control program should be implemented.
Keywords: ESBLs; Gram-negative bacteria; MDR; carbapenemase; fermentative and non- fermentative.
Copyright © 2023 Desalegn, Bitew and Adane.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures
Similar articles
-
Multidrug-resistant profile and prevalence of extended spectrum β-lactamase and carbapenemase production in fermentative Gram-negative bacilli recovered from patients and specimens referred to National Reference Laboratory, Addis Ababa, Ethiopia.PLoS One. 2019 Sep 25;14(9):e0222911. doi: 10.1371/journal.pone.0222911. eCollection 2019. PLoS One. 2019. PMID: 31553773 Free PMC article.
-
Phenotypic characterization of carbapenem non-susceptible gram-negative bacilli isolated from clinical specimens.PLoS One. 2021 Dec 2;16(12):e0256556. doi: 10.1371/journal.pone.0256556. eCollection 2021. PLoS One. 2021. PMID: 34855767 Free PMC article.
-
Multidrug resistance and extended-spectrum beta-lactamase producing Gram-negative bacteria from three Referral Hospitals of Amhara region, Ethiopia.Ann Clin Microbiol Antimicrob. 2021 Mar 11;20(1):16. doi: 10.1186/s12941-021-00422-1. Ann Clin Microbiol Antimicrob. 2021. PMID: 33706775 Free PMC article.
-
Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.Drugs. 2019 Feb;79(3):271-289. doi: 10.1007/s40265-019-1055-2. Drugs. 2019. PMID: 30712199 Review.
-
Treatment of infections caused by multidrug-resistant Gram-negative bacilli: A practical approach by the Italian (SIMIT) and French (SPILF) Societies of Infectious Diseases.Int J Antimicrob Agents. 2024 Jul;64(1):107186. doi: 10.1016/j.ijantimicag.2024.107186. Epub 2024 Apr 28. Int J Antimicrob Agents. 2024. PMID: 38688353 Review.
References
-
- CLSI (2018). Performance standards for antimicrobial susceptibility testing: Twentieth informational supplement. CLSI document M100-S27 (940 Wayne, PA, U.S.A:Edward Bazemore, CDC and Prevention 01/24/2018; ), 36.
-
- Agersew A., Mulat D., Meseret A., Mucheye G. (2013). Uropathogenic bacterial isolates and their antimicrobial susceptibility patterns among HIV/AIDS patients attending gondar university specialized hospital gondar, Northwest Ethiopia. J. Microb. Res. Rev. 1, 42–51. doi: 10.1186/1756-0500-5-197 - DOI
LinkOut - more resources
Full Text Sources